• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»central nervous system therapeutics

Could Praxis Precision Medicines’ Phase 3 ulixacaltamide data redefine the treatment pathway in essential tremor?

By Soujanya Ravi on April 13, 2026   Pharma & Biotech  

Could Praxis Precision Medicines’ Phase 3 ulixacaltamide data redefine the treatment pathway in essential tremor?

Praxis Precision Medicines’ positive Phase 3 ulixacaltamide data could reshape essential tremor treatment. Discover what this means for neurology and investors.

Why Newron’s EUR 38m financing matters for Phase III evenamide development in treatment-resistant schizophrenia

By Pallavi Madhiraju on February 17, 2026   Pharma & Biotech  

Why Newron’s EUR 38m financing matters for Phase III evenamide development in treatment-resistant schizophrenia

Newron Pharmaceuticals secures up to EUR 38 million to advance evenamide Phase III trials. Find out what this means for treatment-resistant schizophrenia.

Clearmind Medicine Inc. and Polyrizon Ltd. target formulation risk in MEAI’s addiction program

By Soujanya Ravi on February 6, 2026   Pharma & Biotech  

Clearmind Medicine Inc. and Polyrizon Ltd. target formulation risk in MEAI’s addiction program

Discover how Clearmind Medicine Inc.’s intranasal MEAI strategy could reshape CNS drug delivery and clinical outcomes. Read the analysis.

Recent Posts

  • Cirius Therapeutics puts CIR-0602K in the spotlight as ADA 2026 turns to metabolic complexity
  • AstraZeneca’s Imfinzi gains a first-mover edge in high-risk non-muscle-invasive bladder cancer
  • Can Ono and Deciphera turn ONO-4578 into a global Phase 3 oncology contender?
  • Ranok Therapeutics pushes RNK08954 forward as KRAS G12D drug development heats up
  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
  • Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
  • Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers
  • Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes